Therapeutic targeting of m6 A modification in cancer. (IMAGE)

Sichuan International Medical Exchange and Promotion Association

Therapeutic targeting of m6 A modification in cancer.

Caption

This figure illustrates the potential of m6 A modification in cancer therapy, including small-molecule inhibitors, RNA-based therapies and delivery systems, combinations with existing cancer therapies, and personalized medicine approaches. a Small-molecule inhibitors include STM2457, Quercetin, UZH1a, and RSM3 for writers, ALK-04, Mupirocin, and CS1 for erasers, Tegaserod, DC-Y13-27, YTHDC1-IN-1, AVJ16, and CWI1-2 for readers. b RNA-based therapies and delivery systems include CRISPR-dCas13-mediated m6A editing and m6 A-targeted siRNA delivery system. c Combination therapies include m6 A combination with chemotherapy, radiotherapy and immunotherapy. d Personalized medicine includes personalized stratification, personalized therapy and personalized monitoring

Credit

Mei Guo

Usage Restrictions

Marked by the credited

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.